Antiviral treatment for preventing postherpetic neuralgia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 2, 2014, Pages

  Chen, Ning ^a   Li, Qifu ^b   Yang, Jie ^a   Zhou, Muke ^a   Zhou, Dong ^a   He, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; PLACEBO; 2 AMINOPURINE; DRUG DERIVATIVE;

ANTIVIRAL THERAPY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; HEADACHE; HERPES ZOSTER; HUMAN; META ANALYSIS (TOPIC); NAUSEA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; META ANALYSIS;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; HUMANS; NEURALGIA, POSTHERPETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901366724     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006866.pub3     Document Type: Review

References (64)

1. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Current Eye Research 1991;10(Suppl):177-82. [PUBMED: 1864092]
2. Huff JC, Bean B, Balfour HH, Laskin OL, Connor JD, Corey L, et al.Therapy of herpes zoster with oral acyclovir. American Journal of Medicine 1988;85(2A):84-9. [PUBMED: 3044099]
3. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. New Zealand Medical Journal 1989;102(863):93-5. [PUBMED: 2648213]
4. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al.Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Annals of Internal Medicine 1995;123(2):89-96. [PUBMED: 7778840]
5. Whitley RJ, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ, Pappas PG, et al.Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Annals of Internal Medicine 1996;125(5):376-83. [PUBMED: 8702088]
6. Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. American Journal of Medicine 1988;85(2A):79-83. [PUBMED: 3044098]
7. Benoldi D, Mirizzi S, Zucchi A, Allegra F. Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. International Journal of Dermatology 1991;30(4):288-90.
8. Cobo LM, Foulks GN, Liesegang T, Lass J, Sutphin JE, Wilhelmus K, et al.Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986;93(6):763-70.
9. Dekonenko EP, Shishov AS, Kupriianova LV, Rudometov IuP, Bagrov FI. Neuralgia and Zovirax treatment of patients with herpes zoster. Terapevticheskii Arkhiv 1998;70(12):63-5. [PUBMED: 10067257]
10. Dekonenko EP, Shishov AS, Kupriianova LV, Rudometov IuP, Bagrov FI. Postherpetic neuralgia in herpes zoster: its treatment with Zovirax. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 1999;99(6):56-8. [PUBMED: 10441870]
11. Esmann V, Ipsen J, Peterslund NA, Seyer-Hansen K, Schønheyder H, Juhl H. Therapy of acute herpes zoster with acyclovir in the nonimmunocompromised host. American Journal of Medicine 1982;73(1A):320-5.
12. Galbraith AW. Prevention of post-herpetic neuralgia by amantadine hydrochloride (Symmetrel). British Journal of Clinical Practice 1983;37(9):304-6.
13. Hoang-Xuan T, Büchi ER, Herbort CP, Denis J, Frot P, Thénault S, et al.Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology 1992;99(7):1062-71.
14. Mandal BK, Dunbar EM, Ellis ME, Ellis J, Dowd P. A double-masked, placebo-controlled trial of acyclovir cream in immunocompetent patients with herpes zoster. Journal of Infection 1988;17(2):57-63.
15. McGill J, MacDonald DR, Fall C, McKendrick GD, Copplestone A. Intravenous acyclovir in acute herpes zoster infection. Journal of Infection 1983;6(2):157-61.
16. Mondelli M, Romano C, Passero S, Porta PD, Rossi A. Effects of acyclovir on sensory axonal neuropathy, segmental motor paresis and postherpetic neuralgia in herpes zoster patients. European Neurology 1996;36(5):288-92.
17. Payne CM, Menday AP, Rogers T, Staughton RC. Isoprinosine does not influence the natural history of herpes zoster or postherpetic neuralgia. Scandinavian Journal of Infectious Diseases 1989;21(1):15-8.
18. van den Broek PJ, van der Meer JW, Mulder JD, Versteeg J, Mattie H. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo controlled study. Infection 1984;12(5):338-41.
19. Varotti C, Rafanelli A. Evaluation of efficacy and tolerance of neuramide in the treatment of herpes zoster and postherpetic neuritis. Drugs under Experimental and Clinical Research 2001;27(5-6):199-208. [PUBMED: 11951578]
20. Wassilew SW, Reimlinger S, Nasemann T, Jones D. Oral acyclovir for herpes zoster: a double-blind controlled trial in normal subjects. British Journal of Dermatology 1987;117(4):495-501.
21. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. New England Journal of Medicine 1994;330(13):896-900.
22. Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia?. Journal of Family Practice 2000;49(3):255-64.
23. Anonymous. Famciclovir: slightly helpful in herpes zoster. Prescrire International 1998;35(7):81-2.
24. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, et al.EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology 2006;13(11):1153-69.
25. Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007795.pub2]
26. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scandinavian Journal of Infectious Diseases 1991;80(Suppl):62-8.
27. Desmond RA, Weiss HL, Arani RB, Soong SJ, Wood MJ, Fiddian PA, et al.Clinical applications for change-point analysis of herpes zoster pain. Journal of Pain and Symptom Management. 2002;23(6):510-6.
28. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004;63(6):959-65.
29. Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. Lancet 1994;343(8913):1648.
30. Dworkin RH, Schmader KE. Epidemiology and natural history of herpes zoster and postherpetic neuralgia. Herpes zoster and postherpetic neuralgia. 2nd Edition. New York: Elsevier Press, 2001:39-64.
31. Fillet AM. Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients. Drugs & Aging 2002;19(5):343-54.
32. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. New England Journal of Medicine 2002;347(5):340-6.
33. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-4.
34. Griffin MJ, Chambers FA, MacSullivan R. Post herpetic neuralgia: a review. Irish Journal of Medical Science 1998;167(2):74-8.
35. Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD005582.pub4]
36. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Medicine/Public Library of Science 2005;2(7):e164.
37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
39. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]
40. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]
41. Intemational Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of Pharmaceuticals for human use adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. International Digest of Health Legislation. 1997; Vol. 48:231-4.
42. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Archives of Internal Medicine 1997;157(8):909-12.
43. Khaliq W, Alam S, Puri NK. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004846.pub2]
44. Kost RG, Straus SE. Postherpetic neuralgia -pathogenesis, treatment, and prevention. The New England Journal of Medicine 1996;335(1):32-42.
45. Lancaster T, Silagy C, Gray S. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. British Journal of General Practice 1995;45(390):39-45.
46. Mahalingam R, Wellish M, Brucklier J, Gilden DH. Persistence of varicella-zoster virus DNA in elderly patients with postherpetic neuralgia. Journal of Neurovirology 1995;1(1):130-3.
47. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. British Medical Journal 1986;293:1529-32.
48. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005;352(22):2271-84.
49. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Annals of Neurology 1986;20(6):651-64.
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
51. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. The Clinical Journal of Pain 2002;18(6):350-4.
52. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. Smith FP. Pathological studies of spinal nerve ganglia in relation to intractable intercostal pain. Surgical Neurology 1978;10(1):50-3.
55. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. American Family Physician 2000;61(8):2437-44, 2447-8.
56. Stratton Hill C. Guidelines for Treatment of Cancer Pain: The Revised Pocket Edition of the Final Report of the Texas Cancer Council's Workgroup on Pain Control in Cancer Patients. 2nd Edition edition. Texas Cancer Council, 1997. Guidelines for Treatment of Cancer Pain: The Revised Pocket Edition of the Final Report of the Texas Cancer Council's Workgroup on Pain Control in Cancer Patients. 2nd Edition. Texas Cancer Council, 1997.
57. Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL. Natural history of pain following herpes zoster. Pain 2007;128(1-2):148-56.
58. Vafai A, Wellish M, Gilden DH. Expression of varicella-zoster virus in blood mononuclear cells of patients with postherpetic neuralgia. Proceedings of the National Academy of Sciences of the United States of America 1988;85(8):2767-70.
59. Wang P, Zhao J, Wu T. Acupuncture for postherpetic neuralgia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007793]
60. Ware JE, Gandek B. Overview of the SF-36 Health-Survey and the International Quality of Life Assesment (IQOLA) Project. Journal of Clinical Epidemiology 1998;51(11):903-12.
61. Ware JE, Gandek B. Overview of the SF-36 Health-Survey and the International Quality of Life Assesment (IQOLA) Project. Journal of Clinical Epidemiology 1998;51(11):903-12.
62. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clinical Infectious Diseases 1996;22(2):341-7.
63. Li Q, He L, Zhang Q, Zhou M, Zhou D. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006866]
64. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006866.pub2]